Loading
Led SOLO-1 and MIRASOL, which gave ovarian cancer a maintenance PARP inhibitor and its first ADC with a survival benefit.
Kathleen Moore was principal investigator of SOLO-1, which showed two years of maintenance olaparib after first-line chemotherapy dramatically extends progression-free survival in BRCA-mutant ovarian cancer and later showed a survival benefit, and of MIRASOL, which showed mirvetuximab soravtansine improves survival in platinum-resistant folate receptor alpha-high disease, the first ADC to do so in ovarian cancer. She is associate director of the GOG Partners programme and leads early-phase gynaecological trials.
Shares PARP, PARP inhibitors, Olaparib, BRCA1 / BRCA2 (HRD) and the tags ovarian, parp.
Shares PARP, PARP inhibitors, Olaparib, BRCA1 / BRCA2 (HRD) and the tags ovarian, parp.
Shares MIRASOL / GOG-3045, Folate receptor alpha, Mirvetuximab soravtansine, PARP.
Shares PARP, PARP inhibitors, Ovarian cancer and the tags ovarian, parp.
Shares PARP, PARP inhibitors, Ovarian cancer and the tags ovarian, trialist.
Shares PARP, PARP inhibitors, Olaparib, BRCA1 / BRCA2 (HRD) and the tag parp.
Shares PARP, PARP inhibitors, BRCA1 / BRCA2 (HRD), Ovarian cancer and the tag parp.
Shares PARP, PARP inhibitors, Olaparib, BRCA1 / BRCA2 (HRD) and the tag parp.